Tomas Heyman - OptiNose Director
| 0OP Stock | EUR 0.38 0.01 2.70% |
Insider
Tomas Heyman is Director of OptiNose since 2020.
| Tenure | 5 years |
| Phone | 267 364 3500 |
| Web | https://www.optinose.com |
OptiNose Management Efficiency
The company has return on total asset (ROA) of (0.312) % which means that it has lost $0.312 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (10.505) %, meaning that it generated substantial loss on money invested by shareholders. OptiNose's management efficiency ratios could be used to measure how well OptiNose manages its routine affairs as well as how well it operates its assets and liabilities.OptiNose has accumulated 126.42 M in total debt. OptiNose has a current ratio of 2.77, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist OptiNose until it has trouble settling it off, either with new capital or with free cash flow. So, OptiNose's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like OptiNose sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for OptiNose to invest in growth at high rates of return. When we think about OptiNose's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Erik Fallstrom | SIVERS SEMICONDUCTORS AB | 56 | |
| Hilde Aasheim | Norsk Hydro ASA | 65 | |
| Carl McMillian | Elanco Animal Health | 51 | |
| Ramiro Cabral | Elanco Animal Health | 51 | |
| Robert Green | SIVERS SEMICONDUCTORS AB | 60 | |
| Ravi Mallela | NMI Holdings | 53 | |
| Larry Cordell | Origin Agritech | 56 | |
| Mike Taylor | Identiv | N/A | |
| Sven Pettersson | SIVERS SEMICONDUCTORS AB | 60 | |
| R Hoover | Elanco Animal Health | 73 | |
| Geoffery Merszei | Origin Agritech | 68 | |
| Edgar Puls | Talanx AG | 50 | |
| Lawrence Kurzius | Elanco Animal Health | 61 | |
| Patric Erlandsson | SIVERS SEMICONDUCTORS AB | 51 | |
| Edward Kirnbauer | Identiv | 58 | |
| James Kang | Origin Agritech | 54 | |
| Kapila Anand | Elanco Animal Health | 65 | |
| Erik Wiklund | SIVERS SEMICONDUCTORS AB | 49 | |
| Bjorn Norrbom | SIVERS SEMICONDUCTORS AB | 72 | |
| David Urbanek | Elanco Animal Health | 56 | |
| Therese Holm | Norsk Hydro ASA | N/A | |
Management Performance
| Return On Equity | -10.5 | |||
| Return On Asset | -0.31 |
OptiNose Leadership Team
Elected by the shareholders, the OptiNose's board of directors comprises two types of representatives: OptiNose inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OptiNose. The board's role is to monitor OptiNose's management team and ensure that shareholders' interests are well served. OptiNose's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OptiNose's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sandra Helton, Independent Director | ||
| Tomas Heyman, Director | ||
| Anthony Krick, VP Officer | ||
| Ramy Mahmoud, President, Chief Operating Officer | ||
| John Messina, Sr Affairs | ||
| Catherine Owen, Director | ||
| Jonathan Neely, VP Operations | ||
| Joshua Tamaroff, Independent Director | ||
| Joseph Scodari, Independent Chairman of the Board | ||
| Keith Goldan, Chief Financial Officer | ||
| Sriram Venkataraman, Independent Director | ||
| Wilhelmus Groenhuysen, Independent Director | ||
| Peter Miller, Chief Executive Officer, Director | ||
| Michele MBA, VP CFO | ||
| Robert ONeil, Independent Director | ||
| Karen Brophy, Chief HR | ||
| William Doyle, Independent Director | ||
| Michael Esq, Chief Sec | ||
| Victor Clavelli, Chief Commercial Officer | ||
| Per MD, CoFounder AS | ||
| Michael Marino, Chief Legal Officer and Corporate Secretary | ||
| MPH MD, Pres COO |
OptiNose Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OptiNose a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.5 | |||
| Return On Asset | -0.31 | |||
| Profit Margin | (0.97) % | |||
| Operating Margin | (0.76) % | |||
| Current Valuation | 257.48 M | |||
| Shares Outstanding | 111.38 M | |||
| Shares Owned By Insiders | 7.36 % | |||
| Shares Owned By Institutions | 77.80 % | |||
| Price To Book | 23.88 X | |||
| Price To Sales | 2.27 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in OptiNose Stock
When determining whether OptiNose offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OptiNose's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Optinose Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Optinose Stock:Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.